Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bifunctional apoptosis regulator (BFAR) is a membrane-bound, endoplasmic reticulum-associated E3 ubiquitin ligase containing a RING finger domain and additional regulatory domains[1][3][4]. It exerts anti-apoptotic functions by inhibiting apoptotic pathways activated by both mitochondrial factors and death receptors[3][5]. BFAR promotes ubiquitination and degradation of specific substrate proteins such as PNPLA3—a factor implicated in lipid metabolism and fatty liver disease[1]—and the Bax inhibitor-1 (BI-1), thereby modulating responses to ER stress and unfolded protein response signaling[3][4]. It is highly expressed in neuronal tissues and protects neurons against a broad range of apoptotic stimuli[5]. BFAR's activity links it to disease roles in cancer, neurodegeneration, and metabolic conditions, but it is not currently a direct target for any approved therapeutic drugs[3][5].
Enhancement or inhibition of ubiquitin ligase activity to regulate substrate degradation Modulation of apoptosis through negative regulation (anti-apoptotic role) Regulation of ER stress responses and unfolded protein response signaling
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bifunctional apoptosis regulator (BFAR).